SCHEDULE 13G/A: Deep Track Capital Reports 4.65% Passive Stake in Springworks Therapeutics

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has reported a passive beneficial ownership of 4.65% in Springworks Therapeutics, Inc. as of December 31, 2024.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively hold a beneficial ownership of 3,460,756 shares of Springworks Therapeutics, Inc. Common Stock.
• This ownership represents 4.65% of the issuer's outstanding Common Stock.
• The shares are held with shared voting power and shared dispositive power.
• The beneficial ownership is reported as of December 31, 2024.
• The filing states that the securities were not acquired and are not held for the purpose of changing or influencing the control of Springworks Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of a passive ownership stake. While not directly indicative of company performance, a significant stake by an investment firm like Deep Track Capital can be viewed as a vote of confidence in the company's long-term prospects, hence a slightly positive sentiment.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a passive investment stake by Deep Track Capital, a specialized investment firm, in Springworks Therapeutics, a biotechnology company. Such filings are standard disclosures for institutional investors holding significant, non-controlling positions in publicly traded companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by an institutional investor like Deep Track Capital may influence investor perception and potentially market sentiment regarding Springworks Therapeutics.

Key Dates

Keywords

Springworks Therapeutics, Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Biotechnology, Investment Firm